Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 12, 1982 - Issue 3
36
Views
21
CrossRef citations to date
0
Altmetric
Research Article

Lindane metabolism by human and rat liver microsomes

, &
Pages 197-202 | Received 17 Aug 1981, Published online: 22 Sep 2008
 

Abstract

1. Human liver microsomes convert lindane (gamma isomer of 1,2,3,4,5,6-hexachloro-cyclohexane) to four major primary metabolites; γ-1,2,3,4,5,6-hexachlorocyclohex-1-ene (3,6/4,5-HCCH), γ-1,3,4,5,6-pentachlorocyclohex-1-ene (3,6/4,5-PCCH), β-1,3,4,5,6-pentachlorocyclohex-1-ene (3,4,6/5-PCCH), and 2,4,6-trichlorophenol (2,4,6-TCP); and two major secondary metabolites; 2,3,4,6-tetrachlorophenol (2,3,4,6-TTCP) and pentachlorobenzene (PCB).

2. Under the same conditions, rat liver microsomes produce 3,6/4,5-HCCH, 2,4,6-TCP and 2,3,4,6-TCCP at rates similar to human liver microsomes. 3,4,6/5-PCCH is produced at much lower rates and 3,6/4,5-PCCH and PCB are not detected when lindane is incubated with rat liver microsomes for up to 30 min.

3. The identity of 3,4,6/5-PCCH, previously not identified as a mammalian metabolite of lindane, is confirmed by column chromatography and g.1.c.-mass spectrometry by comparison with authentic material.

4. It is concluded that there is potentially substantial hepatic metabolism by humans of lindane, a topically used scabicide and pediculicide.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.